Skip to main content
Accessibility
Search
Understanding FA
What is Friedreich’s ataxia?
Signs and Symptoms
Journey to an FA Diagnosis
Genetics of FA
Treating and Managing FA
Newly Diagnosed
What You Need to Know
Connect with Others in the Community
Managing FA
Clinical Management Guidelines
Assembling a Care Team
Treatment for FA
Approved Treatments
For Healthcare Professionals
Terms to Know (Glossary)
Research
Grant Program
Grant Application Process
Grant Types
FARA Funded Grants
Grant Priorities
Opportunities for Young Investigators
Research Resources
Research and Drug Development Tools
Scientific Conferences
Regulatory Interactions
Research Initiatives
FA Global Clinical Consortium
FARA Directed Research
Institutional Supported Programs
Drug Development Pipeline
Participate in Research
Understanding Clinical Trials
Clinical Trial Finder
Tissue Donation Program
Get Involved
Fundraising and Events
rideATAXIA
Energy Ball
Team FARA
Grassroots Fundraising
Participate in Research
Understanding Clinical Trials
Clinical Trial Finder
Ways to Give
Advocate
Current Advocacy Initiatives
Become an Advocate
Advocacy Partnerships
Connect
Educational Events
FARA Ambassador Program
Meet the Ambassadors
Events & News
Events Calendar
News
Blog
Why We Exist
Our History
Our Mission
Our Strategic Plan
FARA Staff
Board of Directors
Scientific Advisory Board
Donate
Home
>
News & Blog
> FDA Awards Fast Track Status to Edison Pharmaceuticals’ EPI-743 for Friedreich’s Ataxia
FDA Awards Fast Track Status to Edison Pharmaceuticals’ EPI-743 for Friedreich’s Ataxia
News
|
Mar 17 2014
Industry News
See all posts
Share
Share
FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
Link to the Press Release